{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:50:34Z","timestamp":1772121034458,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"am","delay-in-days":282,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jiac.2022.05.009","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:30:14Z","timestamp":1654867814000},"page":"1273-1278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population"],"prefix":"10.1016","volume":"28","author":[{"given":"Hitoshi","family":"Kawasuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-6411","authenticated-orcid":false,"given":"Yoshitomo","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Saga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makito","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Murai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitoshi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.05.009_bib1","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.05.009_bib2","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jiac.2022.05.009_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID -19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2022.05.009_bib4","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of Chadox1 nCOV-19 or BNT162b2 in the UK (cov-boost): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2022.05.009_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.05.009_bib6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mrna COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2022.05.009_bib7","series-title":"Tracking SARS-CoV-2 variants","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.jiac.2022.05.009_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jiac.2022.05.009_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced neutralisation of SARS-CoV-2 Omicron B.1.1.529 variant by post-immunisation serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2022.05.009_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jiac.2022.05.009_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2119426","article-title":"Effects of a prolonged booster interval on neutralization of Omicron variant","author":"Zhao","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.05.009_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.05.009_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12985-021-01490-7","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein","volume":"18","author":"Tani","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.jiac.2022.05.009_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00560-21","article-title":"Correlation of the commercial anti- SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants","volume":"9","author":"Morinaga","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jiac.2022.05.009_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00561-21","article-title":"Age-dependent reduction in neutralization against alpha and beta variants of BNT162b2 SARS-CoV-2 vaccine-induced immunity","volume":"9","author":"Kawasuji","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jiac.2022.05.009_bib16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.05.009_bib17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41467-022-28578-0","article-title":"Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies","volume":"13","author":"Re","year":"2022","journal-title":"Nat Com"},{"key":"10.1016\/j.jiac.2022.05.009_bib18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-021-01355-0","article-title":"Delayed production of neutralizing antibodies correlates with fatal COVID-19","volume":"27","author":"Lucas","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jiac.2022.05.009_bib19","doi-asserted-by":"crossref","first-page":"16535","DOI":"10.1038\/s41598-021-96143-8","article-title":"Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19","volume":"11","author":"Kawasuji","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2022.05.009_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jiac.2022.05.009_bib21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jiac.2022.05.009_bib22","article-title":"Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants","author":"Miyamoto","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.jiac.2022.05.009_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.01.019","article-title":"The effect of a third BNT162b2 vaccine on breakthrough infections in healthcare workers: a cohort analysis","author":"Oster","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2022.05.009_bib24","article-title":"Duration of protection of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar","author":"Chemaitelly","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.jiac.2022.05.009_bib25","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.15585\/mmwr.mm7039e4","article-title":"Safety monitoring of an additional dose of COVID-19 vaccine\u2014United States, august 12\u2013september 19, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jiac.2022.05.009_bib26","article-title":"Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization","author":"Doria-Rose","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.jiac.2022.05.009_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13088","article-title":"Advances in neutralization assays for SARS-CoV-2","volume":"94","author":"Lu","year":"2021","journal-title":"Scand J Immunol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:04:05Z","timestamp":1761159845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1341321X22001581"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.05.009","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.23.22271433","asserted-by":"object"}]},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}